5-year period between June 2013 and May 2018. Episodes of a SI were defined as infection requiring admission or use of intravenous antibiotics. For each bDMARD the rate of SI per 100 patient years (PYs) was calculated and patient demographics and comorbidities were analysed. Between group differences were assessed using independent samples t-tests or ANOVA. Where assumptions were violated, Mann-Whitney U tests or Kruskal-Wallis tests were used. For categorical variables, chi-square tests were used, except when assumptions were violated when Fisher's Exact tests were used.

Results: 296 patients received bDMARDs with an overall SI rate of 11.7/100PYs. There was no significant difference in presence of SI by disease type with 24% of patients with rheumatoid arthritis versus 19% with psoriatic arthritis, 14% with ankylosing spondylitis and 29% with "other" ($X^2=3.11$; $df=3$; $p=0.37$). Respiratory tract infections were the most common infection (46%) followed by skin and soft tissue infections (23%). The highest incidence rate of SI occurred with rituximab (29.72 SI/100PYs) followed by certolizumab (22.50 SI/100PYs) and tocilizumab (15.00 SI/100PYs). Duration of time on a bDMARD, disease duration and use of methotrexate or leflunomide were not shown to significantly increase the risk of SI for the entire cohort. The characteristics which were shown to significantly increase SI rates were; prednisone use, increasing age, chronic pulmonary comorbidity and specifically in those with rheumatoid arthritis male gender and total duration of bDMARD use.

Conclusion: In this real-world NQ cohort of patients treated with a bDMARD for a rheumatic disease, we have identified a number of factors potentially contributing to the risk of the development of SIs. This study provides valuable data on SI rates in an Australian 'real-world' cohort that may assist clinicians' choice of bDMARD in patients with a high baseline risk of infection and highlights the importance of minimising prednisone use in patients on bDMARDs.

References:

- [1] Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis*. 2017;76:1093–1101.
- [2] Singh J, Wells G, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev*. 2011;16:CD008794.

Disclosure of Interests: Kate Celkys: None declared, Jason Ly: None declared, Muriel Soden Speakers bureau: Speaker Fees from Pfizer in 2016

DOI: 10.1136/annrheumdis-2020-eular.1137

SAT0582 RISK OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: A NATIONWIDE, POPULATION-BASED COHORT STUDY

H. H. Chen^{1,2}, K. H. Ng², W. C. Chao³, C. H. Lin¹. ¹Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China; ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China; ³Taichung Veterans General Hospital, Department of Critical Care Medicine, Taichung, Taiwan, Republic of China

Background: To date, very few studies had investigated the epidemiology of interstitial lung disease (ILD) among patients with systemic autoimmune rheumatic disease (SARD).

Objectives: To study the risk of interstitial lung disease (ILD) among patients with various systemic autoimmune rheumatic diseases (SARDs) including rheumatoid arthritis (RA), dermatomyositis (DMtis), polymyositis (PM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and primary Sjögren's syndrome (pSS).

Methods: Using 1997–2013 claims data from the Taiwanese National Health Insurance Research Database, we identified 63,277 newly diagnosed patients with various SARDs after excluding those with overlapping SARD diagnoses from 2001–2013 and randomly selected 253,108 non-SARD subjects matching (1:4) SARD patients for SARD diagnosis, age, sex and the year of the index date. We calculated the incidence rates (IRs) of ILD (ICD-9 code 515) in various SARD groups and the corresponding non-SARD comparison groups and estimated the IR ratios (IRRs) with 95% confidence intervals (CI) of ILD development. Using multivariable cox regression analyses, we estimated hazard ratios (HRs) with 95% CIs of ILD in various SARD groups compared with their comparison groups after adjusting for age, sex, Charlson comorbidity index, amiodarone use and methotrexate use. Sensitivity analyses were conducted by using a narrow definition of ILD.

Results: As shown in Table 1, the IRs of ILD were greatest in SSc patients (2,523 per 10⁵ years), followed by patients with DMtis (2,463 per 10⁵ years), PM (1,956 per 10⁵ years), SS (601 per 10⁵ years), RA (279 per 10⁵ years), and SLE (276 per 10⁵ years). Multivariable analyses showed that the risks of ILD were significantly increased in patients with SSc (HR, 66.01; 95% CI, 32.73–133.13), DMtis (128.74, 95% CI, 40.19–412.47), PM (HR, 30.39; 95% CI, 11.24–82.15), pSS (HR, 8.76; 95% CI, 7.03–10.90), RA (HR, 4.22; 95% CI, 3.51–5.08), and SLE (HR, 13.98; 95% CI, 9.25–21.14).

Table 1. Comparison of incidence rates of interstitial lung disease among patients with SARD

SARD	Total	Event (%)	Person-years	Incidence rate (/10 ⁵ years)	IRR (95% CI)
SARD					
Control	253,108	781 (0.3)	1,601,941	49	Reference
SARD	63,277	1,660 (2.6)	380,783	436	8.9 (8.2–9.7)
DMtis					
Control	3,716	10 (0.3)	25,508	39	Reference
DMtis	929	116 (12.5)	4,710	2,463	62.8 (32.9–119.9)
PM					
Control	2,828	9 (0.3)	18,647	48	Reference
PM	707	72 (10.2)	3,681	1,956	40.5 (20.3–81.0)
SSc					
Control	6,224	16 (0.3)	40,789	39	Reference
SSc	1,556	205 (12.2)	8,124	2,523	64.3 (38.7–107.0)
SLE					
Control	52,236	81 (0.2)	366,437	22	Reference
SLE	13,059	230 (1.8)	83,346	276	12.5 (9.7–16.1)
pSS					
Control	60,684	191 (0.3)	326,589	58	Reference
pSS	15,171	471 (3.1)	78,406	601	10.3 (8.7–12.2)
RA					
Control	127,420	474 (0.4)	823,970	58	Reference
RA	31,855	566 (1.8)	202,516	279	4.9 (4.3–5.5)

Conclusion: This nationwide, population-based, matched cohort study demonstrated that the risks of ILD were significantly increased in patients with SARDs.

References:

- [1] Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E, et al. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. *The Journal of rheumatology*. 2011;38(4):693–701.
- [2] Hu Y, Wang LS, Wei YR, Du SS, Du YK, He X, et al. Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients. *Chest*. 2016;149(1):201–8. Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. *Am J Respir Crit Care Med* 2016;194:1514–1522.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.205

SAT0583 DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES

W. S. Chen¹, Y. S. Chang², C. Y. Tsai¹, C. C. Chang³. ¹Division of Allergy, Immunology & Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China; ²Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei, Taiwan, Republic of China; ³Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, Republic of China

Background: The risk of psoriasis in diabetic patients has rarely been explored. **Objectives:** This study aimed to investigate the association between dipeptidyl peptidase-4 (DPP4) inhibitors and the risk of psoriasis in type 2 diabetes mellitus (T2DM) patients.

Methods: We conducted a population-based propensity score-matched cohort study on the basis of Taiwan's National Health Insurance Research Database that included initiators of combination therapy with DPP4i (DPP4i plus metformin) and sulfonylurea (sulfonylurea plus metformin). Psoriasis (PSO) was identified with ≥ 2 diagnoses. Diabetes complications severity index (DCSI) was calculated. A total of 22721 DPP4 initiator and 227684 sulfonylurea initiator were identified. A 1:10 matched-pair cohort based on propensity score (PS) was created. PS-stratified Cox proportional hazards models compared the risk of PSO in DPP4i versus sulfonylurea initiator within 2 years, controlling for potential confounders.

Results: After propensity score matching, 9962 patients with T2DM starting DPP4i combination therapy and 39848 starting sulfonylurea combination therapy were selected. The incidence rate of PSO was lower in DPP4i group (188/100000 person-years) than in sulfonylurea group (467/100000 person-years). Risks of